Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
Early data shows mRNA-4359 may benefit patients with advanced solid cancers
- Post author:
- Post published:September 15, 2024
- Post category:uncategorized
- Post comments:0 Comments